3.Reversible Cerebral Vasoconstriction Syndrome Presenting with Bilateral Occipital Hemorrhage after the Subcutaneous Injection of Synthetic Gonadotropin Releasing Hormone.
Inyoung CHUNG ; Dallah YOO ; Cheolkyu JUNG ; Moon Ku HAN
Journal of the Korean Neurological Association 2017;35(3):151-154
Reversible cerebral vasoconstriction syndrome (RCVS) is a heterogeneous group of cerebrovascular disease. The pathophysiology of RCVS is unknown, but a disturbance in cerebral vascular tone is one of hypothesis. Long-term use of Gonadotropin-releasing hormone (GnRH) agonists can induce a pseudomenopausal state in which estrogen production are suppressed. It might lead to reduced arterial relaxation by estrogen withdrawal. We report a case of RCVS after the injection of synthetic analogue of GnRH.
Cerebral Hemorrhage
;
Cerebrovascular Disorders
;
Estrogens
;
Gonadotropin-Releasing Hormone*
;
Gonadotropins*
;
Hemorrhage*
;
Injections, Subcutaneous*
;
Relaxation
;
Vasoconstriction*
5.Parainfectious Anti-Glial Fibrillary Acidic Protein-Associated Meningoencephalitis
Jae Young JOO ; Dallah YOO ; Tae-Beom AHN
Journal of Movement Disorders 2022;15(1):66-70
Movement disorders associated with glial fibrillary acidic protein (GFAP) autoantibodies have rarely been reported as ataxia or tremors. A 32-year-old man with headache and fever, initially diagnosed with viral meningoencephalitis, showed gradual improvement with empirical treatment. Two weeks after the illness, he suddenly developed orofacial, tongue, and neck dyskinesia accompanied by oculomotor abnormalities, which developed into severe generalized choreoballism. Brain magnetic resonance imaging (fluid-attenuated inversion recovery) showed signal hyperintensities in the bilateral globus pallidus interna. The clinical picture suggested an acute inflammatory trigger of secondary autoimmune encephalitis. The autoimmune antibody test was positive for GFAP, with the strongest reactivity in the cerebrospinal fluid (CSF) before treatment and decreased reactivity in serial CSF examinations during immunotherapy. Dyskinesia gradually improved to the extent that it could be controlled with only oral medications. This patient presented with parainfectious GFAP meningoencephalitis with distinctive clinical features and imaging findings.
7.Smoking Cessation, Weight Change, and Risk of Parkinson’s Disease: Analysis of National Cohort Data
Ryul KIM ; Dallah YOO ; Yu Jin JUNG ; Kyungdo HAN ; Jee-Young LEE
Journal of Clinical Neurology 2020;16(3):455-460
Background:
and Purpose: To determine whether the postcessation weight gain modifies the protective effect of smoking on the development of Parkinson’s disease (PD).
Methods:
This nationwide cohort study included 3,908,687 Korean males aged ≥40 years who underwent at least 2 health checkups biennially between 2009 and 2015. They were grouped into current smokers; quitters with body mass index (BMI) increase, maintenance, and decrease; and never smokers. The occurrence of incident PD was tracked, and Cox proportional-hazard models were used to adjust for potential confounding factors. We also analyzed the impact of weight change regardless of smoking status in the study population.
Results:
There were 6,871 incident PD cases observed during the 13,059,208 person-years of follow-up. The overall risk of PD was significantly lower in quitters than in never smokers [hazard ratio (HR)=0.78, 95% confidence interval (CI)=0.70–0.86]. The risk of PD was still lower in quitters with BMI increase (HR=0.80, 95% CI=0.65–0.98) and in those with BMI maintenance (HR=0.77, 95% CI=0.68–0.87). This tendency was also observed in quitters with BMI decrease (HR=0.76, 95% CI=0.55–1.06), although it was not as robust as in the other two groups.With respect to weight change alone, BMI increase (HR=1.10, 95% CI=1.02–1.18) but not BMI decrease (HR=1.06, 95% CI=0.98–1.14) significantly increased the PD risk compared to BMI maintenance.
Conclusions
Postcessation weight gain in males did not offset the protective impact of smoking on PD development, although overall weight gain predicted an increased risk of PD.
8.Alternating Hemiplegia of Childhood in Korea: a Case Report
Chaewon SHIN ; Dallah YOO ; Han-Joon KIM ; Beomseok JEON
Journal of Korean Medical Science 2020;35(26):e203-
Alternating hemiplegia of childhood (AHC) is a rare neurodevelopmental disorder characterized by recurrent paroxysmal hemiplegic attacks that affect one or the other side of the body. Up to 74% of patients with AHC have a pathologic variant in the ATP1A3 gene. After the introduction of next-generation sequencing, intermediate cases and atypical cases have expanded the clinical spectrum of ATP1A3-related disorders. Herein, we report the first case of AHC in Korea. A 33-year-old man visited our hospital with recurrent hemiplegic and dystonic episode after his first birthday. He was completely normal between episodes and did not have any ataxia, but brain magnetic resonance imaging showed cerebellar atrophy. He also had pes planovalgus deformity. Whole exome sequencing revealed a heterozygous G947R variant in the ATP1A3 gene (c.2839G > C, rs398122887), which is a known pathologic variant. This atypical case of AHC demonstrates the importance of the clinical approach in diagnosing ATP1A3-related disorders.
9.Embolic Infarction with Hypercoagulability Caused by Subclavian Pseudoaneurysm.
Chan Young PARK ; Dallah YOO ; Inyoung CHUNG ; Moon Ku HAN
Journal of the Korean Neurological Association 2017;35(3):166-169
Traumatic subclavian artery injury is a rare complication of clavicular fracture. An arterial injury can present as a pseudoaneurysm, which can cause a hypercoagulable state, thrombus formation, deep vein thrombosis, and distal embolism. We report a case of subclavian artery pseudoaneurysm that presented as embolic stroke in a 81-year-old man at 2015 1 month after clavicular fracture.
Aged, 80 and over
;
Aneurysm, False*
;
Embolism
;
Humans
;
Infarction*
;
Stroke
;
Subclavian Artery
;
Thrombophilia*
;
Thrombosis
;
Venous Thrombosis
10.Spinal Myoclonus Responding to Continuous Intrathecal Morphine Pump.
Jung Eun AHN ; Dallah YOO ; Ki Young JUNG ; Jong Min KIM ; Beomseok JEON ; Myung Chong LEE
Journal of Movement Disorders 2017;10(3):158-160
Spinal myoclonus is a sudden, brief, and involuntary movement of segmental or propriospinal muscle groups. Spinal myoclonus has occasionally been reported in patients undergoing opioid therapy, but the pathophysiology of opioid-induced myoclonus has not been elucidated yet. Here, we present two patients with spinal segmental myoclonus secondary to ischemic and radiation myelopathy. Conventional medications did not help treat persistent myoclonus in both legs. Continuous intrathecal morphine infusion was implanted for pain control in one patient, which relieved spinal myoclonus entirely. This experience led to the application of this method with a second patient, leading to the same gratifying result. Spinal myoclonus reemerged as soon as the morphine pumps were off, which confirmed the therapeutic role of opioids. In contrast to the opioid-induced myoclonus, these cases show a benefit of opioids on spinal myoclonus, which could be explained by synaptic reorganization after pathologic insults in the spinal cord.
Analgesics, Opioid
;
Dyskinesias
;
Humans
;
Leg
;
Methods
;
Morphine*
;
Myoclonus*
;
Spinal Cord
;
Spinal Cord Diseases